IBRX · ImmunityBio, Inc.
$7.10
-0.29% last session
End-of-day data · updated 2026-07-28
Market cap
$7B
Enterprise value
$8B
Trailing P/E
—
Forward P/E
116.5
Dividend yield
—
Beta
0.08
Avg volume
13M
Employees
1K
2D change
-1.55%
5D change
-5.54%
10D change
-8.98%
30D change
-19.75%
60D change
-7.05%
MTD change
-24.02%
YTD change
253.03%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — IBRX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-06-02
Latest call per bank · past 12 months
Jefferies
Buy$9.00
+26.8% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-06-02 | HC Wainwright & Co. | Reiterates | Buy | $15.00 |
| 2026-05-21 | BTIG | Reiterates | Buy | $12.00 |
| 2026-05-20 | HC Wainwright & Co. | Reiterates | Buy | $15.00 |
| 2026-05-05 | D. Boral Capital | Maintains | Buy | $23.00 |
| 2026-04-21 | D. Boral Capital | Maintains | Buy | $23.00 |
| 2026-04-08 | D. Boral Capital | Maintains | Buy | $23.00 |
| 2026-03-26 | D. Boral Capital | Maintains | Buy | $23.00 |
| 2026-03-23 | D. Boral Capital | Maintains | Buy | $23.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 38 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 9.7% below the 50-day MA ($7.72).
- Price vs 200-day MA: Trading 19.1% above the 200-day MA ($5.85).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.15) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($1.98) and high ($11.55).
IBRX Price Chart
Loading chart for IBRX…
Fundamentals
About ImmunityBio, Inc.
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.